Table 1.

Literature search strategy.

‘Infliximab’ AND …; ‘Adalimumab’ AND …; ‘Certolizumab’ AND …
Crohn’s disease OR ulcerative colitis
Immunogenicity
Drug level
Antibodies OR antibody formation
Patient selection
Pharmacoeconomics
Pharmacoeconomics AND (Crohn’s disease OR  ulcerative colitis)
Treatment response
Treatment response AND (Crohn’s disease OR  ulcerative colitis)
Clinical utilities
Outcomes
Patient reported outcomes
Impact of antibody formation
Drug level AND patient response
Antibody formation AND patient response